CU6 — Clarity Pharmaceuticals Cashflow Statement
0.000.00%
- AU$695.59m
- AU$517.34m
Annual cashflow statement for Clarity Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 3.34 | 8.31 | 12 | 16.5 | 16.4 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -13.3 | -27.5 | -43.2 | -54.8 | -92.5 |
| Capital Expenditures | -0.213 | -0.047 | -0.504 | -0.183 | -0.307 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -26.5 | 3.2 | -54.8 | 52.2 | -84.6 |
| Change in Net Investments | |||||
| Cash from Investing Activities | -26.7 | 3.15 | -55.3 | 52 | -84.9 |
| Financing Cash Flow Items | -5.6 | -0.013 | -6.65 | -0.193 | -10.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 86.9 | 0.232 | 115 | 2.21 | 193 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 46.9 | -24.1 | 16.7 | -0.217 | 9.52 |